Levallet G - Search Results

1

Hypoxia-induced activation of NDR2 underlies brain metastases from Non-Small Cell Lung Cancer.

Levallet J, Biojout T, Bazille C, Douyère M, Dubois F, Ferreira DL, Taylor J, Teulier S, Toutain J, Elie N, Bernaudin M, Valable S, Bergot E, Levallet G. Levallet J, et al. Among authors: levallet g. Cell Death Dis. 2023 Dec 13;14(12):823. doi: 10.1038/s41419-023-06345-3. Cell Death Dis. 2023. PMID: 38092743 Free PMC article.

2

Expression of the cAMP-phosphodiesterase PDE4D isoforms and age-related changes in follicle-stimulating hormone-stimulated PDE4 activities in immature rat sertoli cells.

Levallet G, Levallet J, Bouraïma-Lelong H, Bonnamy PJ. Levallet G, et al. Among authors: levallet j. Biol Reprod. 2007 May;76(5):794-803. doi: 10.1095/biolreprod.106.055343. Epub 2007 Jan 10. Biol Reprod. 2007. PMID: 17215491

3

Alterations in proteoglycan synthesis selectively impair FSH-induced particulate cAMP-phosphodiesterase 4 (PDE4) activation in immature rat Sertoli cells.

Levallet G, Levallet J, Bonnamy PJ. Levallet G, et al. Among authors: levallet j. Biochim Biophys Acta. 2007 Apr;1770(4):638-48. doi: 10.1016/j.bbagen.2006.12.006. Epub 2006 Dec 21. Biochim Biophys Acta. 2007. PMID: 17261351

4

FSH-induced phosphoprotein phosphatase 2A-mediated deactivation of particulate phosphodiesterase-4 activities is abolished after alteration in proteoglycan synthesis in immature rat Sertoli cells.

Levallet G, Levallet J, Bonnamy PJ. Levallet G, et al. Among authors: levallet j. J Endocrinol. 2008 Apr;197(1):45-54. doi: 10.1677/JOE-07-0497. J Endocrinol. 2008. PMID: 18372231

5

[Genetic susceptibility for lung cancer and nicotinic addiction: toward a molecular explanation?].

Bergot E, Levallet G, Zalcman G. Bergot E, et al. Among authors: levallet g. Rev Mal Respir. 2008 May;25(5):519-22. doi: 10.1016/s0761-8425(08)71607-3. Rev Mal Respir. 2008. PMID: 18535517 French. No abstract available.

6

[Stage IV NSCLC. Biological treatments of lung cancer in 2008... and in the near future].

Bergot E, Levallet G, Zalcman G. Bergot E, et al. Among authors: levallet g. Rev Mal Respir. 2008 Oct;25(8 Pt 2):3S119-26. Rev Mal Respir. 2008. PMID: 18971836 French.

7

Integrating biomarkers into clinical trials: methodological issues for a new paradigm in nonsmall cell lung cancer.

Zalcman G, Bergot E, Creveuil C, Levallet G, Lechapt E. Zalcman G, et al. Among authors: levallet g. Curr Opin Oncol. 2011 Jan;23(1):106-11. doi: 10.1097/CCO.0b013e3283412eca. Curr Opin Oncol. 2011. PMID: 21076302 Review.

8

[Prognostic and predictive biomarkers in non-small cell lung cancers. From conditioned registrations to routine molecular mapping of lung cancers: Methodological issues].

Bergot E, Levallet G, Creveuil C, Lechapt E, Zalcman G. Bergot E, et al. Among authors: levallet g. Presse Med. 2011 Apr;40(4 Pt 1):379-88. doi: 10.1016/j.lpm.2011.01.016. Epub 2011 Mar 3. Presse Med. 2011. PMID: 21376511 Review. French.

9

O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.

Lechapt-Zalcman E, Levallet G, Dugué AE, Vital A, Diebold MD, Menei P, Colin P, Peruzzy P, Emery E, Bernaudin M, Chapon F, Guillamo JS. Lechapt-Zalcman E, et al. Among authors: levallet g. Cancer. 2012 Sep 15;118(18):4545-54. doi: 10.1002/cncr.27441. Epub 2012 Feb 22. Cancer. 2012. PMID: 22359215 Free article.

10

High TUBB3 expression, an independent prognostic marker in patients with early non-small cell lung cancer treated by preoperative chemotherapy, is regulated by K-Ras signaling pathway.

Levallet G, Bergot E, Antoine M, Creveuil C, Santos AO, Beau-Faller M, de Fraipont F, Brambilla E, Levallet J, Morin F, Westeel V, Wislez M, Quoix E, Debieuvre D, Dubois F, Rouquette I, Pujol JL, Moro-Sibilot D, Camonis J, Zalcman G; Intergroupe Francophone de Cancérologie Thoracique (IFCT). Levallet G, et al. Among authors: levallet j. Mol Cancer Ther. 2012 May;11(5):1203-13. doi: 10.1158/1535-7163.MCT-11-0899. Epub 2012 Mar 12. Mol Cancer Ther. 2012. PMID: 22411898 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

47 results

Search Page